Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
NRIX
#1905
Nurix Therapeutics, Inc. Common stock
15.970
0
+2.70%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+2.70%
Changement Mensuel
-18.42%
Evolution sur 6 mois
+42.46%
Changement Annuel
+42.46%
Clôture Précédente
15.550
0
Open
15.970
0
Bid
Ask
Low
15.970
0
High
15.970
0
Volume
162
Marchés
Actions des Marchés US
Soins de Santé
NRIX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
38.91 M
44.74 M
47.27 M
48.89 M
75.89 M
102.84 M
—
Valuation ratios
Enterprise value
1.54 B
1.21 B
521.24 M
249.49 M
1.52 B
1.49 B
4.06 B
Price to earnings ratio
—
—
-3.34
-2.35
-7.46
-5.54
-18.83
Price to sales ratio
—
—
15.59
4.39
26.44
17.45
56.77
Price to cash flow ratio
—
—
3.77
4.15
8.36
5.87
19.16
Price to book ratio
—
—
1.98
1.69
2.74
2.72
4.24
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.11
0.25
0.43
0.4
0.29
0.38
0.44
Return on equity %
0.15
0.34
0.59
0.72
0.37
0.49
0.59
Return on invested capital %
132.86
270.56
403.07
629.36
713.83
923.04
904.34
Gross margin %
100
100
100
100
100
100
400
Operating margin %
364.66
396.26
476.01
201.41
390.52
340.16
2 220.03
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
242.66
393.93
466.93
186.98
354.85
314.9
2 074.93
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.7
4.7
4.51
3.4
6.46
7.02
25.45
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.07
0.09
0.2
0.11
0.12
0.14
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
3.29
1.5
2.57
2.88
2.95
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
6.36
5.3
9.08
6.84
24.31
Net current asset value per share
—
—
6.55
5.44
9.23
7
25.13
Tangible book value per share
—
—
6.25
3.69
7.85
6.22
21.73
Working capital per share
—
—
5.1
3.84
7.8
6
21.17
Book value per share
—
—
6.25
3.69
7.85
6.22
21.73
Nouvelles
Nurix Therapeutics Stock Sees RS Rating Jump To 82
Ring Christine, directrice juridique de Nurix, vend des actions NRIX pour 237k€
Nurix Therapeutics CFO Hans van Houte sells $61k in shares
Nurix Therapeutics chief legal officer Ring sells $73k in stock
La directrice scientifique de Nurix Therapeutics, Gwenn Hansen, vend des actions pour 81k€
Nurix Therapeutics CSO Gwenn Hansen sells $81k in shares
Stifel relève l’objectif de cours de Nurix à 35€ sur le potentiel de bexobrutideg
Stifel raises Nurix stock price target to $35 on bexobrutideg potential
Piper Sandler relève l’objectif de cours de Nurix à 35€ suite aux plans d’essais pivots
Piper Sandler raises Nurix stock price target to $35 on pivotal trial plans
H.C. Wainwright relève l’objectif de cours de Nurix à 32€ suite aux résultats financiers
H.C. Wainwright raises Nurix stock price target to $32 on financial results